Glucagon - Early breakthroughs and recent discoveries

被引:86
作者
Ahren, Bo [1 ]
机构
[1] Lund Univ, Dept Clin Sci Lund, Lund, Sweden
基金
瑞典研究理事会;
关键词
Glucagon; Glucose; Diabetes; History; HEPATIC GLUCOSE-PRODUCTION; INSULIN-SECRETION; PANCREATIC ALPHA; NERVE-STIMULATION; DIABETIC-PATIENTS; AQUEOUS EXTRACTS; HYPOGLYCEMIA; RECEPTOR; GLP-1; COUNTERREGULATION;
D O I
10.1016/j.peptides.2015.03.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glucagon was discovered in 1922 as a hyperglycemic factor in the pancreas. During its early history up to 1970, glucagon was shown to increase circulating glucose through stimulating glycogenolysis in the liver. It was also shown to be a constituent of islet non-p cells and to signal through G protein coupled receptors and cyclic AMP. Furthermore, its chemical characteristics, including amino acid sequence, and its processing from the preproglucagon gene had been established. During the modern research during the last 40 years, glucagon has been established as a key hormone in the regulation of glucose homeostasis, including a key role for the glucose counterregulation to hypoglycemia and for development of type 2 diabetes, and today glucagon is a potential target for treatment of the disease. Glucagon has also been shown to be a key factor beyond glucose control and involved in many processes. For the coming, future research, studies will be focused on a-cell biology beyond glucagon, hyperglucagonemia in other conditions than diabetes, its involvement in the regulation of body weight and energy expenditure and the potential of glucagon as a target for other diseases than type 2 diabetes, such as type 1 diabetes and obesity. This review summarizes the more than 90 years history of this important hormone as well as discusses potential future research regarding glucagon. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:74 / 81
页数:8
相关论文
共 85 条
[1]   Autonomic regulation of islet hormone secretion -: Implications for health and disease [J].
Ahrén, B .
DIABETOLOGIA, 2000, 43 (04) :393-410
[2]   Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials [J].
Ahren, B. ;
Gautier, J. -F. ;
Berria, R. ;
Stager, W. ;
Aronson, R. ;
Bailey, C. J. .
DIABETES OBESITY & METABOLISM, 2014, 16 (09) :861-868
[3]   Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].
Ahrén, B ;
Landin-Olsson, M ;
Jansson, PA ;
Svensson, M ;
Holmes, D ;
Schweizer, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084
[4]   GLUCAGON IMMUNOREACTIVITY IN PLASMA FROM NORMAL AND DYSTROPHIC MICE [J].
AHREN, B ;
LUNDQUIST, I .
DIABETOLOGIA, 1982, 22 (04) :258-263
[5]   Differential impairment of glucagon responses to hypoglycemia, neuroglycopenia, arginine, and carbachol in alloxan-diabetic mice [J].
Ahrén, B ;
Taborsky, GJ ;
Havel, PJ .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (01) :12-19
[6]   β- and α-Cell Dysfunction in Subjects Developing Impaired Glucose Tolerance Outcome of a 12-Year Prospective Study in Postmenopausal Caucasian Women [J].
Ahren, B. .
DIABETES, 2009, 58 (03) :726-731
[7]   THE MECHANISM OF VAGAL NERVE-STIMULATION OF GLUCAGON AND INSULIN-SECRETION IN THE DOG [J].
AHREN, B ;
TABORSKY, GJ .
ENDOCRINOLOGY, 1986, 118 (04) :1551-1557
[8]   SYMPATHETIC-NERVE STIMULATION VERSUS PANCREATIC NOREPINEPHRINE INFUSION IN THE DOG .1. EFFECTS ON BASAL RELEASE OF INSULIN AND GLUCAGON [J].
AHREN, B ;
VEITH, RC ;
TABORSKY, GJ .
ENDOCRINOLOGY, 1987, 121 (01) :323-331
[9]   GIP-LIKE IMMUNOREACTIVITY IN GLUCAGON CELLS INTERACTIONS BETWEEN GIP AND GLUCAGON ON INSULIN RELEASE [J].
AHREN, B ;
HAKANSON, R ;
LUNDQUIST, I ;
SJOLUND, K ;
SUNDLER, F .
ACTA PHYSIOLOGICA SCANDINAVICA, 1981, 112 (03) :233-242
[10]   Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes [J].
Ahren, Bo .
VASCULAR HEALTH AND RISK MANAGEMENT, 2013, 9 :155-163